A community-added intervention entry. General facts are kept separate from personal usage and tracking.
What it is, why people use it, the evidence, and what to know before trying it.
Regulatory status: dietary supplement / next-generation probiotic (live forms) or postbiotic (pasteurized cells) in the United States. Not a medication. Not an FDA-approved drug for weight, diabetes, insulin resistance, or gut barrier. Pendulum Glucose Control is marketed in the US as a medical food for the dietary management of type 2 diabetes (physician-supervised claim; not a drug approval). In the EU, only the pasteurized form is an authorised novel food (see §7)
**Live *A. muciniphila* isolate — confidence: weak.** One 9-completer arm (Depommier) was milder than pasteurized. One 58-person Chinese T2D RCT (Zhang 2025) was **null overall**; any weight/HbA1c movement was in a low-baseline subgroup and partly within-group. Colonisation seems to fail when the gut already has a lot of Akkermansia. That is a hypothesis with two small human tests, not a prescribing rule. **Pasteurized *A. muciniphila* MucT — confidence: weak-to-moderate (context-specific).** Depommier 2019 is real: **verified** 3-month RCT, pasteurized 10^10/day, insulin sensitivity **+28.6%** and insulin **−34%** vs placebo, cholesterol **−8.7%**, LPS down, weight **−2.3 kg (P = 0.091)**. It is also tiny, imbalanced at baseline, and author-patented. The larger insulin-sensitivity RCT (**n = 142, 30 billion/day**) **failed its Matsuda primary**. The 2026 Maastricht trial is the strongest weight number: **~2 kg less regain** over 24 weeks after an 8-week diet (company-funded). Net: pasteurized MucT is the only form with repeated human RCTs; ITT metabolic effects are **small or absent** except after a diet and in people with **low baseline Akkermansia**.